What is RPRX's health score?

Royalty Pharma plc (RPRX) has a TradeApes health score of 45 out of 100, rated Mixed. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is RPRX's estimated fair value?

Based on our 5-year discounted cash flow model, Royalty Pharma plc's estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is RPRX undervalued or overvalued?

Our model currently rates RPRX as Undervalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

To Unlock Full Report

4 free score cards remaining

Royalty Pharma plc (RPRX)

Healthcare Undervalued medium mixed

$56.43

Updated: 2026-07-13

TradeApes Score

Financial Strength

45 Mixed

Operating Trend

50 Mixed

Relative Value

45 Mixed

Capital Allocation

20 Stressed

Risk Management

70 Healthy

Key Findings

+ High FCF yield — above 7%, strong cash return relative to price paid

Unlock Full Report →

− Very high leverage — net debt/EBITDA above 5×

Unlock Full Report →

Industry Related Stocks

ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) Aardvark Therapeutics, Inc. (AARD) Abivax S.A. (AAVXF) Ascend Wellness Holdings, Inc. (AAWH) AbbVie Inc. (ABBV) AbCellera Biologics Inc. (ABCL)

See all Healthcare stocks →

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.